These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28748122)

  • 1. Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.
    Eleftheriadis T; Golphinopoulos S; Pissas G; Stefanidis I
    J Adv Res; 2017 Sep; 8(5):555-560. PubMed ID: 28748122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
    Jeon HJ; Oh J; Shin DH
    PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
    Tiku A; Johnson DW; Badve SV
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):346-352. PubMed ID: 33767063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials.
    Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W
    Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775
    [No Abstract]   [Full Text] [Related]  

  • 5. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
    Sampson AL; Singer RF; Walters GD
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009460. PubMed ID: 29084343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of conducting a trial of uric-acid-lowering therapy in CKD.
    Badve SV; Brown F; Hawley CM; Johnson DW; Kanellis J; Rangan GK; Perkovic V
    Nat Rev Nephrol; 2011 May; 7(5):295-300. PubMed ID: 21321568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into uric acid effects on the progression and prognosis of chronic kidney disease.
    Filiopoulos V; Hadjiyannakos D; Vlassopoulos D
    Ren Fail; 2012; 34(4):510-20. PubMed ID: 22260409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate reduction and renal preservation: what is the evidence?
    Macías N; Goicoechea M; de Vinuesa MS; Verdalles U; Luño J
    Curr Rheumatol Rep; 2013 Dec; 15(12):386. PubMed ID: 24203097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.
    Ejaz AA; Nakagawa T; Kanbay M; Kuwabara M; Kumar A; Garcia Arroyo FE; Roncal-Jimenez C; Sasai F; Kang DH; Jensen T; Hernando AA; Rodriguez-Iturbe B; Garcia G; Tolan DR; Sanchez-Lozada LG; Lanaspa MA; Johnson RJ
    Semin Nephrol; 2020 Nov; 40(6):574-585. PubMed ID: 33678312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uric acid in CKD: has the jury come to the verdict?
    Bonino B; Leoncini G; Russo E; Pontremoli R; Viazzi F
    J Nephrol; 2020 Aug; 33(4):715-724. PubMed ID: 31933161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
    Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
    Kanji T; Gandhi M; Clase CM; Yang R
    BMC Nephrol; 2015 Apr; 16():58. PubMed ID: 25928556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y
    BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
    Oh TR; Choi HS; Kim CS; Bae EH; Ma SK; Sung SA; Kim YS; Oh KH; Ahn C; Kim SW
    Sci Rep; 2019 Apr; 9(1):6681. PubMed ID: 31040373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.
    Srivastava A; Kaze AD; McMullan CJ; Isakova T; Waikar SS
    Am J Kidney Dis; 2018 Mar; 71(3):362-370. PubMed ID: 29132945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.
    Perrenoud L; Kruse NT; Andrews E; You Z; Chonchol M; Wu C; Ten Eyck P; Zepeda-Orozco D; Jalal D
    Kidney Med; 2020; 2(2):155-161. PubMed ID: 32964203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.